For more information call
+44 (0)844 736 9016
or email us here
Mawdsleys and Oncoscience GMbH have launched a Named Patient Supply Program to allow Oncologists in the United Kingdom (UK) and Ireland to obtain access to CIMAher® (Nimotuzumab) on an unlicensed basis for the treatment of various types of cancer.
Mawdsleys are hosting a webinar to help people in the healthcare sector and pharmaceutical industry develop a deeper understanding of Named Patient Programmes.
Mawdsleys warmly welcomes three new colleagues to support our capability to provide regulatory and pharmaceutical services. Qualified Person (QP) Phil Millward and BDMs Angela McDermott (Clinical Trials Service) and Daniel Belcher (Regulatory and QP Services) all joined the team in May.
Helping ensure patients have access to the drugs they need, when they need them.
Select from the following Worldwide sites...×